Kittang, Astrid Olsnes

My main research focus is to optimize the characterization of MDSC in myelodysplastic syndrome to find new therapeutic targets.

Models available:

Human myelodysplastic syndrome

Cells available:


Technology available:

Multiparameter flow cytometry, Helios mass cytometer and Aria cell sorter.

Key publications related to Mye-EUNITER:

Kittang AO, Kordasti S, Sand KE, Costantini B, Kramer AM, Perezabellan P, Seidl T, Rye KP, Hagen KM, Kulasekararaj A, Bruserud Ø, Mufti GJ. Expansion Of Myeloid Derived Suppressor Cells Correlates With Number Of T Regulatory Cells And Disease Progression In Myelodysplastic Syndrome. Oncoimmunology. 2015 Jun 24;5(2).

Sand K, Theorell J, Bruserud Ø, Bryceson YT, Kittang AO. Reduced Potency Of Cytotoxic T Lymphocytes From Patients With High-Risk Myelodysplastic Syndromes Cancer Immunol Immunother.2016 Sep;65:1135-47.

Sand KE, Rye KP, Mannsåker B, Bruserud O, Kittang AO. Expression Patterns Of Chemokine Receptors On Circulating T Cells From Myelodysplastic Syndrome Patients. Oncoimmunology. 2013 Feb 1;2(2).

Kittang AO, Sand K, Brenner AK, Rye KP, Bruserud Ø. The Systemic Profile Of Soluble Immune Mediators In Patients With Myelodysplastic Syndromes. Int J Mol Sci. 2016 Jul 5;17(7).

Olsnes AM, Ersvaer E, Ryningen A, Paulsen K, Hampson P, Lord JM, Gjertsen BT, Kristoffersen EK, Bruserud Ø. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology, 2009, Vol.145(6), p.761-774.